Focused On-demand Library for Transcription initiation factor TFIID subunit 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P49848

UPID:

TAF6_HUMAN

Alternative names:

RNA polymerase II TBP-associated factor subunit E; Transcription initiation factor TFIID 70 kDa subunit; Transcription initiation factor TFIID 80 kDa subunit

Alternative UPACC:

P49848; A4D2B2; A4D2B3; B4DT11; D6W5U2; Q6AI29

Background:

Transcription initiation factor TFIID subunit 6, also known as TAF6, plays a pivotal role in the initiation of RNA polymerase II-dependent transcription. It is a part of the TFIID basal transcription factor complex, crucial for recognizing and binding promoters, facilitating the assembly of the pre-initiation complex. TAF6's ability to form homodimers connects various modules of the TFIID complex, establishing a structural core essential for transcriptional regulation.

Therapeutic significance:

TAF6's involvement in transcriptional regulation and apoptosis, particularly through its role in up-regulating genes like GADD45A and CDKN1A/p21, highlights its potential in influencing cell fate decisions. Its association with Alazami-Yuan syndrome underscores the therapeutic significance of understanding TAF6's function. Exploring TAF6's mechanisms could unveil novel therapeutic strategies for managing diseases linked to transcriptional dysregulation.